C4 Therapeutics, Inc. (NASDAQ:CCCC) filed its quarterly report on Form 10-Q for the period ended June 30, 2026, with the U.S. Securities and Exchange Commission on August 11, 2026.

Key Highlights

  • Shares outstanding: As of July 31, 2026, the company had 123,025,136 shares of common stock, $0.0001 par value per share, outstanding.
  • Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company, and is not an emerging growth company.
  • Shell company status: The registrant indicated it is not a shell company as defined in Rule 12b-2 of the Exchange Act.
  • Collaborations disclosed: The filing references existing collaboration agreements with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co., Ltd., and Merck KGaA, Darmstadt, Germany.
  • Profitability outlook: The company disclosed it "expect[s] to incur losses over at least the next several years and may never achieve or maintain profitability."

C4 Therapeutics Q2 2026 Quarterly Report: Key Disclosures

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company headquartered at 490 Arsenal Way, Suite 120, Watertown, MA 02472, filed its Form 10-Q for the quarterly period ended June 30, 2026. The company's common stock is listed on the Nasdaq Global Select Market under the ticker CCCC, with a par value of $0.0001 per share. As of July 31, 2026, the registrant reported 123,025,136 shares of common stock outstanding.

According to the filing, C4 Therapeutics confirmed it has filed all reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and has been subject to filing requirements for the past 90 days. The company also confirmed it submitted all required Interactive Data Files electronically pursuant to Rule 405 of Regulation S-T during the same period. The registrant identified itself as a non-accelerated filer and a smaller reporting company.

The filing contains forward-looking statements, which the company cautioned "are based on our management's beliefs and assumptions and on information currently available to our management" and are "subject to known and unknown risks, uncertainties, and other factors." Among the risk factors summarized, the company disclosed that it "will need substantial additional funding to pursue our business objectives" and that, if unable to raise capital when needed, it "may be required to delay, limit, reduce or terminate" its research or product development programs. The filing references the company's TORPEDO platform and ongoing collaboration agreements with Roche, Betta Pharmaceuticals, and Merck KGaA, Darmstadt, Germany.

What Was Disclosed

C4 Therapeutics filed its Form 10-Q for the quarter ended June 30, 2026, reporting 123,025,136 shares outstanding as of July 31, 2026, and disclosing its classification as a non-accelerated, smaller reporting company with ongoing third-party collaborations and anticipated continued operating losses.